The third vaccine, Russia’s Sputnik V, was authorised for emergency use on Tuesday morning, giving India’s Covid-19 battle a new lease on life, even as the second wave continued to show every sign of being more widespread than the first. In addition, the Centre has expedited emergency approvals for foreign-produced Covid-19 vaccines that have received Emergency Use Authorization (EUA) in other countries, in order to broaden the vaccine portfolio for domestic use and accelerate vaccination coverage. For the second day in a row, the nation has seen over 160,000 cases.
The vaccine arithmetic is more important than ever before, with the Russian vaccine due to be added to the mix. India had set a target of inoculating 300 million people by the end of July, and it is clear that both public health and political considerations would force the target to be reached, if not exceeded.
India is the world’s largest vaccine producer, with the Serum Institute of India being the largest single manufacturing company. Bharat Biotech’s ability is currently insufficient in comparison to SII, which manufactures the Oxford-AstraZeneca vaccine Covishield. SII is attempting to expand its power. Here’s the most recent update.
Covid vaccine Covishield manufacturing development & capability plans from the Serum Institute of India
The Department of Biotechnology told a Parliamentary Committee in March that the total monthly output of Covishield is 70-100 million doses. SII’s production capacity is nearly 70 million doses per month, according to more recent studies, and plans to raise it to 100 million doses per month have been delayed by a January fire at one of its Pune headquarters’ units. SII has so far supplied the government with over 100 million doses and shipped 30 million to the COVAX alliance.
SII is also in talks to produce Russia’s Sputnik V, which has been approved by the drug regulator DCGI, and hopes to launch Novovax’s Covovax vaccine by September if all of the required approvals are in place. The efficacy of Covishield ranges from 61% to 90%, with publishers using a figure of 79 percent for this reason.
Covaxin vaccine development and capability plans at Bharat Biotech
Along with the approval for Sputnik V, Bharat Biotech has announced that it will increase production of the indigenous vaccine Covaxin at its manufacturing facilities in Hyderabad and Bengaluru. The company expects a projected production capacity of 150 million doses per year, and it is currently expanding monthly production from 5 million doses per month to 12 million doses per month as part of its recent expansion.
The Hyderabad-based vaccine manufacturer hopes to increase production to 500 million doses a year in the future. It has requested Rs 150 crore in financing, which will be divided between its Hyderabad and Bengaluru facilities. According to clinical trial results, Bharat Biotech’s Covaxin has an efficacy of 81 percent.
Sputnik V vaccine:
According to news, Dr Reddy’s Laboratories, which partnered with Russia’s RIDF eight months ago, has a contract to distribute 100 million doses of the vaccine, which it will import while setting up its own manufacturing.
Apart from Dr Reddy’s, Virchow Biotech, Gland Pharma, and Hetero Drug in Hyderabad, as well as Bengaluru-based Stelis Biopharma, will produce a total of 752 million doses (planned), but when this will happen is unknown. As previously said, SII is also involved. According to the Lancet, the Sputnik V vaccine has a 91.6 percent efficacy rate.
Vaccine Maitri manages India’s internal vaccine inoculation, vaccine shipments, and grants
Vaccinations are currently being delivered at a rate of around 4 million per day, with a total of 108.5 million doses administered as of April 13, including 13 million second doses. Since India crossed the milestone of 100 million vaccine doses, 80 million of the vaccines given out were Covishield, which was produced by SII.
Source 1: Republic Bharat
At the same time, India’s Vaccine Maitri initiative, according to the Ministry of External Affairs, has exported or provided vaccines to nearly 90 countries and organisations, including UN peacekeepers. Grants account for 10.5 million of these, while commercial exports account for: COVAX shipments total 35.8 million, with 18.7 million in the United States. As a result, India has delivered 65 million vaccines worldwide.
So far, the country has completed almost 260 million studies, with 13.6 million confirmed Covid-19 cases and 1.26 million active cases at the moment. In India, the Coronavirus has claimed the lives of 171,058 people.